Sex based subgroup differences in randomized controlled trials: Empirical evidence from Cochrane meta-analyses

BMJ (Online)

Volumn 355, Issue , 2016, Pages

  Wallach, Joshua D ^a   Sullivan, Patrick G ^a   Trepanowski, John F ^a   Steyerberg, Ewout W ^b   Ioannidis, John P A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COCHRANE LIBRARY; DATA EXTRACTION; DECISION SUPPORT SYSTEM; EPIDEMIOLOGICAL DATA; FEMALE; FREQUENCY ANALYSIS; HUMAN; MALE; META ANALYSIS (TOPIC); METHODOLOGY; ONLINE SYSTEM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SEX RATIO; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; VALIDITY; BLOOD; CAROTID ENDARTERECTOMY; CAROTID STENOSIS; CHEMICALLY INDUCED; HYPERPROLACTINEMIA; INCIDENCE; LUNG NEOPLASMS; META ANALYSIS; OUTCOME ASSESSMENT; STATISTICAL BIAS; STATISTICS AND NUMERICAL DATA; STROKE;

BENZODIAZEPINE DERIVATIVE; OLANZAPINE; PROLACTIN; RISPERIDONE;

BENZODIAZEPINES; BIAS (EPIDEMIOLOGY); CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; HYPERPROLACTINEMIA; INCIDENCE; LUNG NEOPLASMS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROLACTIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SEX FACTORS; STROKE;

EID: 84999142168     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i5826     Document Type: Article

References (58)

1. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-9. doi:10.1016/S0140-6736(00)02039-0.
2. Bhandari M, Devereaux PJ, Li P, et al. Misuse of baseline comparison tests and subgroup analyses in surgical trials. Clin Orthop Relat Res 2006;447:247-51. doi:10.1097/01.blo.0000218736.23506.fe.
3. Hernández AV, Boersma E, Murray GD, Habbema JD, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?Am Heart J 2006;151:257-64. doi:10.1016/j.ahj.2005.04.020.
4. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med 1987;317:426-32. doi:10.1056/NEJM198708133170706.
5. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94. doi:10.1056/NEJMsr077003.
6. Hingorani AD, Windt DA, Riley RD, et al. PROGRESS Group. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ 2013;346:e5793. doi:10.1136/bmj.e5793.
7. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4. doi:10.1056/NEJMp1006304.
8. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-5. doi:10.1056/NEJMp1500523.
9. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60. doi:10.2165/00003088-200544010-00002.
10. Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34:203-18. doi:10.2165/00003088-199834030-00003.
11. Legato MJ. Gender and the heart: sex-specific differences in normal anatomy and physiology. J Gend Specif Med 2000;3:15-8.
12. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003;42:107-21. doi:10.2165/00003088-200342020-00001.
13. Drici MD, Clément N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001;24:575-85. doi:10.2165/00002018-200124080-00002.
14. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-7. doi:10.1001/jama.1993.03510210076031.
15. Xhyheri B, Bugiardini R. Diagnosis and treatment of heart disease: are women different from men?Prog Cardiovasc Dis 2010;53:227-36. doi:10.1016/j.pcad.2010.07.004.
16. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917-30. doi:10.1002/sim.1296.
17. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 2006;354:1667-9. doi:10.1056/NEJMp068070.
18. Kasenda B, Schandelmaier S, Sun X, et al. DISCO Study Group. Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. BMJ 2014;349:g4539. doi:10.1136/bmj.g4539.
19. Sun X, Briel M, Busse JW, et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review. BMJ 2011;342:d1569. doi:10.1136/bmj.d1569.
20. Sun X, Briel M, Busse JW, et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ 2012;344:e1553. doi:10.1136/bmj.e1553.
21. Iqbal SA, Wallach JD, Khoury MJ, Schully SD, Ioannidis JP. Reproducible Research Practices and Transparency across the Biomedical Literature. PLoS Biol 2016;14:e1002333. doi:10.1371/journal. pbio.1002333.
22. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78-84. doi:10.7326/0003-4819-116-1-78.
23. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallelgroup randomised trials. Lancet 2001;357:1191-4. doi:10.1016/S0140-6736(00)04337-3.
24. Kaner EF, Beyer F, Dickinson HO, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev 2007;2:CD004148.
25. Cortés-Jofré M, Rueda JR, Corsini-Munõz G, Fonseca-Cortés C, Caraballoso M, Bonfill Cosp X. Drugs for preventing lung cancer in healthy people. Cochrane Database Syst Rev 2012;10:CD002141.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. doi:10.1016/0197-2456(86)90046-2.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015;45(Pt A):139-45.
28. Viechtbauer W. Conducting meta-analyses in R with the metaphor package. J Stat Softw 2010;36:1-48.
29. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 2014;14:25. doi:10.1186/1471-2288-14-25.
30. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015;10:CD009580.
31. Rerkasem K, Rothwell PM. Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev 2011;(4):CD001081.
32. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013;(5):CD003382.
33. Gallo MF, Grimes DA, Lopez LM, Schulz KF. Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev 2006;(1):CD003550.
34. Komossa K, Rummel-Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2011;(1):CD006626.
35. Moran PS, Teljeur C, Ryan M, Smith SM. Systematic screening for the detection of atrial fibrillation. Cochrane Database Syst Rev 2016;6:CD009586.
36. Hartley L, Flowers N, Holmes J, et al. Green and black tea for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;(6):CD009934.
37. Mohler E III, Fairman R. Management of symptomatic carotid atherosclerotic disease. In: Kasner S, Eidt, JF., Mills, JL., Dashe, JF., Collins, KA., eds. Waltham, MA: UpToDate; 2016.
38. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4. doi:10.1001/jama.1994.03510350050036.
39. January CT, Wann LS, Alpert JS, et al. ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-104. doi:10.1161/CIR.0000000000000040.
40. Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47. doi:10.1093/eurheartj/ehs253.
41. Kumar K. Overview of Atrial Fibrillation. In: Zimetbaum P, Saperia, GM., ed. Waltham, MA: UpToDate; 2016.
42. Bond R, Warlow CP, Naylor AR, Rothwell PM. European Carotid Surgery Trialists' Collaborative Group. Variation in surgical and anaesthetic technique and associations with operative risk in the European carotid surgery trial: implications for trials of ancillary techniques. Eur J Vasc Endovasc Surg 2002;23:117-26. doi:10.1053/ejvs.2001.1566.
43. Kernan WN, Ovbiagele B, Black HR, et al. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-236. doi:10.1161/STR.0000000000000024.
44. Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV. The Effects of Antipsychotics on Prolactin Levels and Women's Menstruation. Schizophr Res Treatment 2013; 2013:502697.
45. Klimas J, Tobin H, Field CA, et al. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Cochrane Database Syst Rev 2014;(12):CD009269.
46. Hoe VC, Urquhart DM, Kelsall HL, Sim MR. Ergonomic design and training for preventing work-related musculoskeletal disorders of the upper limb and neck in adults. Cochrane Database Syst Rev 2012;(8):CD008570.
47. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;(2):CD003639.
48. Sarcoma Meta-analysis Collaboration (SMAC). Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev 2000;(2):CD001419.
49. Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. JAMA 2012;308:1676-84. doi:10.1001/jama.2012.13444.
50. Fajardo-Bernal L, Aponte-Gonzalez J, Vigil P, et al. Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections. Cochrane Database Syst Rev 2015;(9):CD011317.
51. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010;11:85. doi:10.1186/1745-6215-11-85.
52. Riley RD, Hayden JA, Steyerberg EW, et al. PROGRESS Group. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 2013;10:e1001380. doi:10.1371/journal. pmed.1001380.
53. Italiano A.Prognostic or predictive? It's time to get back to definition!J Clin Oncol 2011;29:4718; author reply 4718-9. doi:10.1200/JCO.2011.38.3729.
54. van Klaveren D, Vergouwe Y, Farooq V, Serruys PW, Steyerberg EW. Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions. J Clin Epidemiol 2015;68:1366-74. doi:10.1016/j.jclinepi.2015.02.012.
55. U.S. National Institutes of Health. Consideration of Sex as a Biological Variable in NIH-funded Research. http://orwh.od.nih.gov/resources/pdf/NOT-OD-15-102-Guidance.pdf
56. U.S. National Institutes of Health. Consideration of Sex as a Biological Variable in NIH-funded Research (NOT-OD-15-102). http://grants.nih. gov/grants/guide/notice-files/NOT-OD-15-102.html
57. Doull M, Runnels V, Tudiver S, Boscoe M. Sex and Gender in Systematic Reviews Planning Tool. 2011. methods.cochrane.org/sites/methods.cochrane.org.equity/files/public/uploads/SRTool-PlanningVersionSHORTFINAL.pdf
58. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117. doi:10.1136/bmj.c117.